Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study

Launched by SHENYANG MEDICAL COLLEGE · Jun 30, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called Cold Atmospheric Plasma (CAP) for people with moderate to severe acne, a common skin condition that causes pimples and inflammation. Traditional acne treatments can sometimes cause side effects or stop working well, so this study is testing whether CAP—a technology that uses special gases to help kill bacteria and heal the skin—can be a safe and effective option.

Adults between 18 and 40 years old who have moderate to severe acne (with many pimples) may be eligible to join the study, as long as they agree to use birth control during the treatment and meet other health requirements. Pregnant or breastfeeding women, people with certain allergies, recent antibiotic use, or other serious health issues cannot participate. While in the study, participants will receive treatment using one of two CAP devices developed by the researchers, and their skin’s response and safety will be carefully monitored. This trial has not started recruiting yet, but it offers hope for a new, possibly better way to manage stubborn acne.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18-40 years;
• • Clinically diagnosed with acne vulgaris, with moderate to severe disease (Pillsbury grade III or IV, lesion count ≥50);
• • Will agree to use effective contraception during the treatment period;
• • Will sign a written informed consent form.
• Exclusion Criteria:
• • Pregnant or breastfeeding women;
• • Known allergy to any active component of CAP;
• • Use of systemic antibiotics within 4 weeks prior to enrollment;
• • Presence of dyslipidemia or other severe systemic diseases;
• • Participation in other clinical trials within the past 3 months or currently enrolled in another clinical trial.